RHUMBLINE ADVISERS - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 93 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,381,239
-35.8%
82,809
+6.3%
0.00%0.0%
Q2 2023$2,151,901
+125156.2%
77,911
+4.3%
0.00%0.0%
Q1 2023$1,718
+121.4%
74,709
+5.0%
0.00%
+100.0%
Q4 2022$776
-99.9%
71,153
+0.9%
0.00%0.0%
Q3 2022$594,000
+12.7%
70,517
+5.9%
0.00%0.0%
Q2 2022$527,000
-52.0%
66,566
+43.4%
0.00%0.0%
Q1 2022$1,099,000
-26.9%
46,426
+5.6%
0.00%
-50.0%
Q4 2021$1,504,000
+98.7%
43,969
+3.0%
0.00%
+100.0%
Q3 2021$757,000
-58.7%
42,695
+4.6%
0.00%
-50.0%
Q2 2021$1,832,000
+113.0%
40,812
+22.9%
0.00%
+100.0%
Q1 2021$860,000
+26.5%
33,215
-1.5%
0.00%0.0%
Q4 2020$680,000
+18.1%
33,735
+14.6%
0.00%0.0%
Q3 2020$576,000
+9.9%
29,446
-0.8%
0.00%0.0%
Q2 2020$524,000
+344.1%
29,676
+78.0%
0.00%
Q1 2020$118,000
+2.6%
16,671
+2.3%
0.00%
Q4 2019$115,000
-38.5%
16,291
+4.8%
0.00%
Q3 2019$187,000
+19.9%
15,540
+20.7%
0.00%
Q2 2019$156,000
+77.3%
12,878
+25.1%
0.00%
Q1 2018$88,000
-50.6%
10,294
+2.0%
0.00%
Q3 2017$178,000
+56.1%
10,096
+0.2%
0.00%
Q2 2017$114,00010,0760.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$19,373,0004.95%
Bain Capital Life Sciences Investors, LLC 2,260,572$17,881,0002.10%
Finepoint Capital LP 735,126$5,815,0002.01%
Altium Capital Management LP 365,100$2,888,0001.16%
RTW INVESTMENTS, LP 4,794,499$37,924,0000.98%
Amitell Capital Pte Ltd 50,129$397,0000.90%
COWEN AND COMPANY, LLC 1,065,724$8,430,0000.81%
Tri Locum Partners LP 155,000$1,226,0000.50%
BVF INC/IL 1,106,838$8,755,0000.42%
HighVista Strategies LLC 46,459$367,0000.22%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders